Abbott’s AI-powered coronary imaging platform receives FDA approval
Abbott’s new AI-powered coronary imaging platform has received FDA approval, the company announced on Aug. 3. The solution, Ultreon Software, combines optical coherence tomography (OCT) with advanced AI algorithms to provide a complete view of the patient’s coronary blood vessels.
The software was designed to help interventional cardiologists make key treatment decisions, measure blood vessels, guide stents and more. Back in April, it gained CE mark approval.
“As cardiologists continue to adopt OCT and move away from traditional imaging methods such as angiography, emerging technologies are pivotal to determine the best course of patient care,” Nick West, MD, chief medical officer and divisional vice president of global medical affairs for Abbott's vascular business, said in a statement. “AI enables Ultreon Software to automatically detect calcium and vessel diameters allowing doctors to put stents exactly where they are needed.”
“Ultreon Software guides stents to be placed with precision,” added Ziad Ali, MD, DPhil, a cardiologist at St. Francis Hospital and Heart Center in New York City. “These types of innovative technologies are instrumental in providing the best care for our patients."
Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.